Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR.70/IL15-transduced/TGFBR2KO CB-NK cells in Relapsed/Refractory Myeloid Malignancies
NCT06930651Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TGFBR2 KO CAR.70/IL-15 NK cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2025; status: recruiting.
02
Drugs
TGFBR2 KO CAR.70/IL-15 NK cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06930651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930651.